INS and kidney disorder: Compared with other CVOTs involving GLP-1RA, participants in the AMPLITUDE-O trial had the longest duration of diabetes (15 years), lowest mean eGFR (72 ml/min/1.73 m2) with a higher percentage (32%) of people with renal disease (eGFR 25–60 mL/min), highest glycosilated hemoglobin (8.9%), and highest percentage of insulin use (62%) or sodium–glucose transporter-2 inhibitors (SGLT-2i) (15%) at baseline, thus identifying a more fragile population.